Phase II Trial of Venetoclax and HMA in FLT3 Mutated AML Patients
A phase II trial is comparing azacitidine and venetoclax to a combination of azacitidine, venetoclax, and gilteritinib in older patients with FLT3 mutated AML.
Indication
Clinical and regulatory intelligence for Acute Myeloid Leukemia with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.